Analyst Price Targets — ARQT
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 26, 2026 11:40 am | Doug Tsao | H.C. Wainwright | $34.00 | $27.01 | StreetInsider | Arcutis Biotherapeutics Inc. (ARQT) PT Raised to $34 at H.C. Wainwright |
| November 28, 2025 11:32 am | Uy Ear | Mizuho Securities | $37.00 | $30.96 | StreetInsider | Arcutis Biotherapeutics Inc. (ARQT) PT Raised to $37 at Mizuho |
| October 30, 2025 11:29 am | Richard Law | Goldman Sachs | $29.00 | $25.41 | TheFly | Arcutis Biotherapeutics price target raised to $29 from $19 at Goldman Sachs |
| October 29, 2025 10:20 am | Douglas Tsao | H.C. Wainwright | $30.00 | $24.95 | TheFly | Arcutis Biotherapeutics price target raised to $30 from $22 at H.C. Wainwright |
| October 29, 2025 10:11 am | Uy Ear | Mizuho Securities | $32.00 | $24.95 | StreetInsider | Arcutis Biotherapeutics Inc. (ARQT) PT Raised to $32 at Mizuho |
| March 11, 2025 5:59 pm | — | Jefferies | $19.00 | $15.49 | TheFly | Arcutis Biotherapeutics price target raised to $19 from $16 at Jefferies |
| December 30, 2024 11:08 am | Douglas Tsao | H.C. Wainwright | $19.00 | $14.20 | TheFly | Arcutis Biotherapeutics initiated with a Buy at H.C. Wainwright |
| May 15, 2024 7:15 am | Serge Belanger | Needham | $18.00 | $8.13 | StreetInsider | Arcutis Biotherapeutics Inc. (ARQT) PT Raised to $18 at Needham |
| May 15, 2024 5:18 am | Uy Ear | Mizuho Securities | $18.00 | $8.13 | StreetInsider | Arcutis Biotherapeutics Inc. (ARQT) PT Raised to $18 at Mizuho |
| January 2, 2024 4:07 pm | — | Mizuho Securities | $8.00 | $3.43 | StreetInsider | Arcutis Biotherapeutics Inc. (ARQT) PT Raised to $8 at Mizuho Securities, Upgraded to Buy |
Latest News for ARQT
WESTLAKE VILLAGE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovation in immuno-dermatology, today announced that Christopher “Chris” Peetz has been appointed to the Arcutis Board of Directors effective July 15, 2026.
WESTLAKE VILLAGE, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will report its second quarter 2026 financial results and provide a business update after the U.S. financial markets close on Wednesday, August 5, 2026.
Biotech stock Arcutis is in a buy zone and Wall Street is looking for the skin-diseases drugmaker to expand the use of its key cream, Zorvye.
FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of February 23, 2027 Application supported by positive results from Phase 2 open-label INTEGUMENT-INFANT study and Phase 1 open-label pharmacokinetic (PK) study 1 million children under the age of 2 are treated topically for atopic dermatitis in the United States, representing 10% of all adults and children treated topically for atopic…
Arcutis doubled revenue last year while Vertex delivered strong profits and cash flow. Explore how each company stacks up on growth, risk, and value.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ARQT.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.